Hypopituitarism
Template:DiseaseDisorder infobox
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2] Iqra Qamar M.D.[3]
For patient information click here
Synonyms and keywords: Pituitary failure, Adenohypophyseal hyposecretion, Panhypopituitarism
Overview
Template:DiseaseDisorder infobox
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2], Ahmed Elsaiey, MBBCH [3]
Overview
Hypopituitarism is referred to the deficiency of one of the pituitary gland hormones or more while the deficiency of all pituitary hormones is known as panhypopituitarism. A study comprising two cross-sectional surveys showed the prevalence of hypopituitarism to be 29 per 100,000 individual in the first survey and 45.5 per 100,000 individual in the second survey. Hypopituitarism can be classified on the basis of the anatomical location of pathology into primary (pituitary) and secondary (hypothalamic) hypopituitarism. It can also be classified on the basis of the portion of gland involvement into partial or complete glandular involvement. The pathophysiology of hypopituitarism mainly involves ischemic injury of the pituitary gland. The ischemia may be due to hemorrhage, tumors, brain injury, and compression or occlusion of the hypophyseal blood vessels. Causes of hypopituitarism may be classified based upon the etiology such as congenital or acquired. Common congenital causes include idiopathic, anatomic lesion in the sella turcica and CNS malformations. Common acquired causes may include pituitary macroadenoma, craniopharyngioma, surgery, radiation, traumatic brain injury, Sheehan’s syndrome, apoplexy, SAH, meningitis, hypophysitis, meningioma, lymphoma, hemochromatosis and Wegner’s granulomatosis. Less common causes include peri-natal insults, genetic causes, and pituitary hypoplasia or aplasia. Hypopituitarism should be differentiated from other diseases causing panhypopituitarism, hypothyroidism, hypogonadism, ACTH deficiency, GH deficiency, ADH deficiency and high prolactin level. Common risk factors in the development of hypopituitarism may include pituitary tumor or space occupying lesion, pituitary apoplexy, severe blood loss such as Sheehan’s syndrome, pituitary surgery, cranial radiation, genetic defects, hypothalamic disease, immunosuppression, inflammatory processes, pituitary infarction and non-compliance with hormone replacement therapy. Less common risk factors include infiltrative disorders, traumatic brain injury causing skull fractures, ischemic stroke and subarachnoid hemorrhage. Screening of hypopituitarism has been recommended for the patients with traumatic brain injury and patients with a history of radiation exposure on the head. The natural history of hypopituitarism depends on the severity of damage leading to partial or complete hormonal deficiency. If left untreated can lead to critical consequences. Complications of hypopituitarism include adrenal crisis, osteoporosis, electrolyte abnormalities, and diabetes mellitus. Hypopituitarism is often associated with vascular conditions and has a high mortality rate. Hypopituitarism has a good prognosis as long as the hormonal replacement therapy is given adequately. A positive history of head trauma, adenoma, a lesion such as a sellar lesion, or any symptom related to pituitary hormonal deficiency is suggestive of hypopituitarism. Patients of hypopituitarism may be asymptomatic or show symptoms which can be nonspecific or specific for the deficient hormone. Patients with acute onset of hypopituitarism can present with a headache, nausea, vomiting, visual impairment, fatigue, cold intolerance, hypotension, and dizziness. Patients with chronic hypopituitarism can present with pallor, weight loss, and anorexia. Clinical presentation in hypopituitarism depends upon the onset, the severity of hormonal deficiency and the number of deficient hormones. A subnormal or reduced concentration of pituitary hormones is diagnostic of hypopituitarism. Patients with complete hormonal deficiencies are mostly symptomatic and have low serum concentrations of both, the pituitary hormones as well as the target-organ hormones. Patients having partial hormonal deficiencies are detected by dynamic tests/stimulatory tests such as corticotropin stimulation, insulin-induced hypoglycemia, and metyrapone test. MRI scan with intravenous gadolinium is the imaging procedure of choice in the diagnosis of hypopituitarism. It is preferred over the CT scan as optic chiasm, pituitary stalk, and cavernous sinuses can be seen in MRI. Treatment involves appropriate hormone replacement therapy, which must be taken for the rest of your life that results in significant improvement and reversal of not only the physical symptoms but also the psychological symptoms. Conditions that need a surgical consideration may include pituitary apoplexy , microadenomas with GH or ACTH hypersecretion and debulking macroadenomas with mass symptoms and resistant to medical therapy. Hypopituitarism can be prevented by good obstetric care, minimizing radiation exposure and high-resolution microscopic hypophyseal surgery done by experienced neurosurgeons.
Historical Perspective
Hypopituitarism was first described by Dr. Simmonds for the first time in 1914. Dr. Yalow and Berson discovered the radioimmunoassay in 1950. Causes of the hypopituitarism were being described through the 20th and 21st centuries.
Classification
Hypopituitarism can be classified on the basis of location of pathology into primary or secondary hypopituitarism. It can also be classified on the basis of the extent of gland involved into partial or complete glandular involvement.
Pathophysiology
Hypopituitarism occurs secondary to ischemia of the pituitary gland. This ischemia can be due to hemorrhage, tumors, or brain injury. Compression of the blood vessels is one of the mechanisms that cause ischemia to the pituitary gland and leads to hypopituitarism. Pituitary adenomas cause compression of the hypophyseal vessels leading to interruption in the blood supply of the pituitary gland. Traumatic brain injury either primary or secondary also leads to pituitary gland dysfunction.
Causes
Causes of hypopituitarism can be classified based upon the etiology into congenital or acquired. Common congenital causes include idiopathic, anatomiclesion in the sella turcica and CNS malformations. Common acquired causes may include pituitary macroadenoma, craniopharyngioma, surgery, radiation,traumatic brain injury, Sheehan’s syndrome, apoplexy, SAH, meningitis, hypophysitis, meningioma, lymphoma, hemochromatosis and Wegner’s granulomatosis. Less common causes include Peri-natal insults, genetic causes, such as Kallman syndrome, Pallister-Hall syndrome, Rieger syndrome, and pituitary hypoplasia or aplasia.
Differentiating Hypopituitarism from Other Diseases
Hypopituitarism should be differentiated from other diseases causing panhypopituitarism, hypothyroidism, hypogonadism, ACTH deficiency, GH deficiency,ADH deficiency and high prolactin level.
Epidemiology and Demographics
In a longitudinal survey (1992-1999), the incidence of hypopituitarism was estimated to be 4.2 cases per 100,000. A study comprising two cross-sectional surveys showed the prevalence of hypopituitarism to be 29 – 45.5 per 100.000 individual.
Risk Factors
Common risk factors in the development of hypopituitarism may include pituitary tumor or space occupying lesion, pituitary apoplexy, severe blood loss such as Sheehan’s syndrome, pituitary surgery, cranial radiation, genetic defects, hypothalamic disease, immunosuppression, inflammatory processes,pituitary infarction and non-compliance with hormone replacement therapy. Less common risk factors include infiltrative disorders, traumatic brain injurycausing skull fractures, ischemic stroke and subarachnoid hemorrhage.
Screening
Screening of hypopituitarism has been recommended for the patients with traumatic brain injury and patients with a history of radiation exposure on the head.
Natural History, Complications, and Prognosis
The natural history of hypopituitarism depends on the severity of damage leading to partial or complete hormonal deficiency. If left untreated, hypopituitarism can lead to critical consequences. Complications of hypopituitarism include adrenal crisis, osteoporosis, electrolyte abnormalities anddiabetes mellitus. Hypopituitarism is often associated with vascular conditions. Hypopituitarism has a good prognosis as long as the hormonal replacement therapy is given adequately.
Diagnosis
History and Symptoms
A positive history of head trauma, adenoma, a lesion such as a sellar lesion, or any symptom related to pituitary hormonal deficiency is suggestive ofhypopituitarism. Patients of hypopituitarism may be asymptomatic or show symptoms which can be nonspecific or specific for the deficient hormone. Patients with acute onset of hypopituitarism can present with a headache, nausea, vomiting, visual impairment, fatigue, cold intolerance, hypotension, anddizziness. Patients with chronic hypopituitarism can present with pallor, weight loss, and anorexia.
Physical Examination
Clinical presentation in hypopituitarism depends upon the onset, the severity of hormonal deficiency and the number of deficient hormones. Patients with hypopituitarism are ill-appearing and usually look tired. Physical examination of patients with hypopituitarism is usually remarkable for the respectivehormonal deficiency and present with features of that specific hormone such as hypothyroidism presents as delayed relaxation of tendon reflexes,bradycardia, coarse skin, puffy facies, and loss of eyebrows. ACTH deficiency can present with postural hypotension, tachycardia, and weight loss.Gonadotropin deficiency may present with breast atrophy, soft testes, and regression of sexual characteristics. Growth hormone deficiency can present with short stature, decreased sweating with impaired thermogenesis, and reduced muscle mass.
Laboratory Findings
A subnormal or reduced concentration of pituitary hormones is diagnostic of hypopituitarism. Patients with complete hormonal deficiencies are mostlysymptomatic and have low serum concentrations of both, the pituitary hormones as well as the target-organ hormones. Patients having partial hormonaldeficiencies are detected by dynamic tests/stimulatory tests such as corticotropin stimulation, insulin-induced hypoglycemia and metyrapone test.Corticotropin deficiency is detected by assessing basal cortisol secretion. Patients with intermediate cortisol levels need to be tested foradrenocorticotrophic hormone (ACTH) reserve. There are several tests to check the ACTH reserve. Metyrapone test is preferred over others as it is applicable to all adults with no age restriction and has good correlation with stress related cortisol response. Patients with hypopituitarism are screened forhypothyroidism by measuring thyroxine, total thyroxine (T4) and triiodothyronine (T3) uptake, and free T4. Gonadotropin deficiency is confirmed with lowestradiol, low testosterone, and low/normal serum FSH/LH. Growth hormone deficiency is confirmed with provocative tests (insulin induced hypoglycemiaand arginine and GHRH combination) for GH secretion resulting in subnormal levels of serum GH levels, serum insulin-like growth factor-1 levels lower than the age-specific lower limit of normal and deficiency of more than one pituitary hormones e.g ACTH, TSH, and gonadotropins. ADH deficiency is assessed by water deprivation test and ADH suppression test. Prolactin deficiency can be confirmed by directly measuring prolactin levels on more than 1 occasion as its secretion is episodic but it is not done routinely as it is not clinically significant.
Electrocardiogram
There are no electrocardiogram findings associated with hypopituitarism.
X ray
There are no X ray findings associated with hypopituitarism.
CT scan
CT scan is preferred over MRI for visualization of calcification in a meningioma or a craniopharyngioma. Routine CT is insensitive to the diagnosis unless frank intracranial hemorrhage is present.The pituitary mass may be evident and be hyperdense.
MRI
MRI is the imaging procedure of choice in the diagnosis of hypopituitarism. It is preferred over the CT scan as optic chiasm, pituitary stalk, and cavernous sinuses can be seen in MRI. An MRI lesion needs to be related to clinical and lab findings. The absence of an MRI lesion mostly indicates a non-organic etiology. Cystic lesions, such as Rathke’s cleft cysts may have a low-intensity signal on T1-weighted images and a high-intensity signal on T2-weighted images. Meningiomas have a homogenous postcontrast enhancement than pituitary adenomas and have a suprasellar attachment. Hemorrhage into the pituitary gland results in a high-intensity signal on both T1- and T2-weighted images.
Ultrasound
There are no ultrasound findings associated with hypopituitarism.
Other imaging findings
There are no other specific imaging findings for hypopituitarism.
Other diagnostic studies
Other diagnostic findings may include serum and CSF angiotensin converting enzyme activities, serum ferritin to rule out hemochromatosis, human chorionic gonadotrophin (HCG) and genetic testing.
Treatment
Medical Therapy
The mainstay of treatment for hypopituitarism is hormone replacement therapy and treating the underlying cause. Adrenocorticotrophic hormone (ACTH) deficiency is treated with glucocorticoids. Gonadotropin deficiency is treated with testosterone in men and estrogen with or without progesterone in women.Hypothyroidism is treated with levothyroxine. Growth hormone (GH) is usually replaced in children and replaced in adults only if symptomatic and after replacement of all other pituitary hormones.
Surgery
The feasibility of surgery depends on the clinical condition and underlying etiology. Conditions that need a surgical consideration may include pituitary apoplexy, microadenomas with growth hormone (GH) or adrenocorticotrophic hormone (ACTH) hypersecretion and debulking macroadenomas with masssymptoms and resistant to medical therapy.
Primary Prevention
Hypopituitarism can be prevented by good obstetric care, minimizing radiation exposure and high-resolution microscopic hypophyseal surgery done by experienced neurosurgeons.
Secondary Prevention
Secondary prevention may be done by long-term monitoring of patients for complications of hormonal replacement therapy and by dose adjustments in stressful situations.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Hypopituitarism was first described by Dr. Simmonds for the first time in 1914. Dr. Yalow and Berson discovered the radioimmunoassay, in 1950. Causes of the hypopituitarism were being described through the 20th and 21st centuries.
Historical Perspective
- In 1914, Dr. Simmonds was the first one to describe hypopituitarism. He described it as the inability of the pituitary gland to secrete hormones matching the organs need.[1]
- In 1950, Dr. Yalow and Berson discovered the radioimmunoassay, which helped with the measurement of the pituitary hormones for the diagnosis of hypopituitarism. Previously, it was based on only the presenting signs and symptoms of the patients.[2]
- In 1973, combined stimulation tests of insulin, gonadotrophin releasing hormone (GnRH), and thyroid releasing hormone (TRH) were performed for the first time, to assess the pituitary gland function.[3]
- Through the 20th and 21st centuries, causes of the hypopituitarism were further explained.
References
- ↑ Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E (2007). “Hypopituitarism”. Lancet. 369 (9571): 1461–70. doi:10.1016/S0140-6736(07)60673-4. PMID 17467517.
- ↑ Prozesky OW (1979). “Measles vaccination”. S Afr Med J. 55 (7): 236. PMID 441860.
- ↑ Harsoulis P, Marshall JC, Kuku SF, Burke CW, London DR, Fraser TR (1973). “Combined test for assessment of anterior pituitary function”. Br Med J. 4 (5888): 326–9. PMC 1587416. PMID 4202260.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Hypopituitarism can be classified on the basis of location of pathology into primary or secondary hypopituitarism. It can also be classified on the basis of the extent of gland involved into partial or complete glandular involvement.
Classification
Hypopituitarism can be classified on the basis of location of pathology and the extent of glandular involvement:[1]
Classification on the basis of anatomical location:
- Primary hypopituitarism: Represents intrinsic pathology in pituitary and decreased pituitary hormone levels
- Secondary hypopituitarism: Represents pathology in hypothalamus and decreased hypothalamic hormone levels
Classification on the basis of extent of glandular involvement
- Partial hypopituitarism: Means deficiency of one or more than one hormones (can be anterior or posterior pituitary gland lobe)
- Complete/Panhypopituitarism: Means deficiency of all of the pituitary hormones (both anterior and posterior lobes)
References
- ↑ Lamberts, SWJ; de Herder, WW; van der Lely, AJ (1998). “Pituitary insufficiency”. The Lancet. 352 (9122): 127–134. doi:10.1016/S0140-6736(98)85043-5. ISSN 0140-6736.
Pathophysiology
Template:DiseaseDisorder infobox
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2], Iqra Qamar M.D.[3]
Overview
Hypopituitarism occurrs secondarly to ischemia of the pituitary gland. This ischemia can be due to hemorrhage, tumors, or brain injury. Compression of the blood vessels is one of the mechanisms that cause ischemia to the pituitary gland and leads to hypopituitarism. Pituitary adenomas cause compression of the hypophyseal vessels leading to interruption in the blood supply of the pituitary gland. Traumatic brain injury either primary or secondary also leads to pituitary gland dysfunction.
Pathophysiology
Background on pituitary gland blood supply
- In order to understand the pathophysiology of hypopituitarism, it is necessary to know the blood supply of the pituitary gland, because hypopituitarism occurs mainly by ischemia through different mechanisms like hemorrhage, tumors or brain injury.[1][2]
- The pituitary gland is composed of two parts anterior (adenohypophysis) and posterior (neurohypophysis). Both parts are supplied by the carotid arteries.
- Adenohypophysis: It receives blood supply from the long and short hypophyseal arteries, which arise from the internal carotid artery and the anterior portion of the circle of Willis.
- Neurohypophysis: It receives the blood supply from the inferior and middle hypophyseal arteries.

Anterior pituitary (Adenohypophysis)
- Anterior pituitary does not have a direct blood supply and is supplied by the hypophyseal portal system.
- The hypophyseal portal system is a fenestrated set of capillaries that allows rapid exchange of hormones between the hypothalamus and anterior pituitary.
- Occlusion of the blood supply and other vascular abnormalities of the hypophyseal portal system may also cause complications with the exchange of hormones between the hypothalamus and the pituitary gland leading to hypopituitarism.
Posterior pituitary (Neurohypophysis)
- Posterior pituitary has its own blood supply via inferior hypophyseal artery and is less commonly affected as compared to anterior pituitary.
- If posterior pituitary is affected, it can result in neurohypophseal dysfunction and ischemic necrosis of thirst center leading to increased osmotic threshold for thirst onset.[4]
Hypothalamic and pituitary hormones with their action on the target glands
| Hypothalamic hormone | Axis involved | Mode of action | Pituitary hormone
or target organ |
Action | |
|---|---|---|---|---|---|
| Anterior pituitary hormones | Thyrotropin-releasing hormone | Hypothalmic-pituitary-thyroid (HPT) axis
![]() |
Stimulatory | Thyrotropin | Stimulates triiodothyronine and thyroxine production |
| Corticotropin-releasing hormone | Hypothalmic-pituitary-adrenal (HPA) axis
![]() |
Stimulatory | Corticotropin | Stimulates production of cortisol and adrenal androgens | |
| Stimulatory | Prolactin | Stimulates milk production from breasts in females | |||
| Gonadotropin-releasing hormone | Hypothalamus pituitary testicles (HPG) axis
![]() |
Stimulatory |
| ||
| Dopamine | Inhibitory | Prolactin | _ | ||
| Growth hormone-releasing hormone |
![]() |
Stimulatory | Growth hormone | Stimulates insulin-like growth factor 1 production | |
| Somatostatin | Inhibitory | Growth hormone | _ | ||
| Posterior pituitary hormones | Vasopressin | Stimulatory | Stimulates free water reabsorption in the collecting ducts | ||
| Oxytocin | Stimulatory | Breast, uterus | Stimulates milk ejection and uterine contraction |
Pathogenesis
- Hypopituitarism occurrs mainly due to the destruction of the pituitary gland cells via ischemia, inflammation or infiltration. However, ischemia is believed to be the cornerstone of the pathogenesis of hypopituitarism.[9][10]
Compression of the blood vessels
- Pituitary adenoma (secretory or non-secretory) is one of the common causes of compression of the hypophyseal vessels resulting in ischemia.[11]
- Large adenomas (more than 1.5 cm) cause greater loss of function than microadenomas. They cause compression (due to a greater mass effect) of the pituitary stalk and the hypophyseal portal vessels, which supply the pituitary gland with blood.
- The tumor growth in the pituitary gland participates in increasing the intrasellar pressure, which causes a decrease in the hypophyseal blood flow leading to a decrease of hormonal delivery from the hypothalamus to the pituitary gland.
- Pituitary gland enlargement due to hypertrophy and hyperplasia of lactotrophic cells in anterior pituitary result in superior hypophyseal artery compression, which may be complicated by decreased portal pressure and vasospasm during delivery, playing an important role in the pathogenesis of Sheehan’s syndrome leading to hypopituitarism.[12]
(d) Meningioma
Traumatic brain injury (TBI)
Hypopituitarism may occur via any of the following mechanisms:
(b) Trauma
- The anatomical sitting of the pituitary gland increases its susceptibility to getting injured from trauma.
- It is believed that tissue necrosis results in the release of sequestered antigens, precipitating autoimmunity of the pituitary gland and hypopituitarism in Sheehan’s syndrome.[13][14][15]
(c) Brain injury due to other events like hypotension or hypoxia
Genetics
Hypopituitarism is caused by a mutation in any one of the following genes.[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]
| Isolated
hormonal abnormalities |
Gene | Inheritance
[Autosomal Recessive (AR), Autosomal Dominant (AD), X-linked (XL)] |
Phenotype |
|---|---|---|---|
| GH1 | AD, AR | Isolated GH deficiency | |
| GHRHR | AR | Isolated GH deficiency | |
| TSHB | AR | Isolated TSH deficiency | |
| TRHR | AR | Isolated TSH deficiency | |
| TPIT | AR | Isolated ACTH deficiency | |
| GnRHR | AR | HH | |
| PC1 | AR | ACTH deficiency, hypoglycemia, HH, obesity | |
| POMC | AR | ACTH deficiency, obesity, red hair | |
| DAX1 | XL | Adrenal hypoplasia congenital and HH | |
| CRH | AR | CRH deficiency | |
| KAL1 | XL | Kallman syndrome, renal agenesis, synkinesia | |
| FGFR1 | AD, AR | Kallman syndrome, cleft lip and palate, facial dysmorphism | |
| Leptin | AR | HH, obesity | |
| Leptin-R | AR | HH, obesity | |
| GPR54 | AR | HH | |
| Kisspeptin | AR | HH | |
| FSHB | AR | Primary amenorrhea, defective spermatogenesis | |
| LHB | AR | Delayed puberty | |
| PROK2 | AD | Kallman syndrome, severe sleep disorder, obesity | |
| PROKR2 | AD, AR | Kallman syndrome | |
| AVP-NPII | AR, AD | Diabetes insipidus | |
| Combined pituitary hormone deficiency | POU1F1 | AR, AD | GH, TSH, and prolactin deficiencies |
| PROP1 | AR | GH, TSH, LH, FSH, prolactin, and evolving ACTH deficiencies | |
| Specific syndromes | HESX1 | AR, AD | Septo-optic dysplasia |
| LHX3 | AR | GH, TSH, LH, FSH, prolactin deficiencies, limited neck rotation | |
| LHX4 | AD | GH, TSH, ACTH deficiencies with cerebellar abnormalities | |
| SOX3 | XL | Hypopituitarism and mental retardation | |
| GLI2 | AD | Holoprosencephaly and multiple midline defects | |
| SOX2 | AD | Anophthalmia, hypopituitarism, oesophageal atresia | |
| GLI3 | AD | Pallister-Hall syndrome | |
| PITX2 | AD | Rieger syndrome |
Gross pathology
- The predominant finding is hemorrhage with or without necrosis.
- Pale, necrotic material is particularly found when there is a long interval between the acute clinical event and surgery.
Microscopic pathology
On microscopy, the following findings may be observed:
- Ischemic necrosis leading to scarring of neurohypophysis
- Scarring of paraventricular and supraoptic nuclei
- Electron microscopic shows evidence of abnormal fenestration of tumor vessels (pituitary adenoma) with fragmented basal membranes that may predispose the patient to hemorrhage

References
- ↑ Dusick JR, Wang C, Cohan P, Swerdloff R, Kelly DF (2012). “Pathophysiology of hypopituitarism in the setting of brain injury”. Pituitary. 15 (1): 2–9. doi:10.1007/s11102-008-0130-6. PMC 4170072. PMID 18481181.
- ↑ Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E (2007). “Hypopituitarism”. Lancet. 369 (9571): 1461–70. doi:10.1016/S0140-6736(07)60673-4. PMID 17467517.
- ↑ Henry Gray (1918) Anatomy of the Human Body, Bartleby.com: Gray’s Anatomy, Plate 721, Public Domain, <https://commons.wikimedia.org/w/index.php?curid=541543>
- ↑ Atmaca H, Tanriverdi F, Gokce C, Unluhizarci K, Kelestimur F (2007). “Posterior pituitary function in Sheehan’s syndrome”. Eur. J. Endocrinol. 156 (5): 563–7. doi:10.1530/EJE-06-0727. PMID 17468192.
- ↑ All used images are in public domain. Public Domain<https://commons.wikimedia.org/w/index.php?curid=8567011>
- ↑ CC BY-SA 3.0 <https://commons.wikimedia.org/w/index.php?curid=23363130>
- ↑ Acraciaderivative work: Boghog2 – Testosterona-ciclo.png, CC BY-SA 3.0, <https://commons.wikimedia.org/w/index.php?curid=11186183>
- ↑ Used with permission. All used images are in public domain., Public Domain,<https://commons.wikimedia.org/w/index.php?curid=6699074>
- ↑ Arafah BM (2002). “Medical management of hypopituitarism in patients with pituitary adenomas”. Pituitary. 5 (2): 109–17. PMID 12675508.
- ↑ Vance, Mary Lee (1994). “Hypopituitarism”. New England Journal of Medicine. 330 (23): 1651–1662. doi:10.1056/NEJM199406093302306. ISSN 0028-4793.
- ↑ Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000). “The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas”. J Clin Endocrinol Metab. 85 (5): 1789–93. doi:10.1210/jcem.85.5.6611. PMID 10843153.
- ↑ Scheithauer BW, Sano T, Kovacs KT, Young WF, Ryan N, Randall RV (1990). “The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases”. Mayo Clin. Proc. 65 (4): 461–74. PMID 2159093.
- ↑ Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N (2002). “Pituitary autoimmunity in patients with Sheehan’s syndrome”. J. Clin. Endocrinol. Metab. 87 (9): 4137–41. doi:10.1210/jc.2001-020242. PMID 12213861.
- ↑ “AUTOANTIBODIES IN SHEEHAN’S SYNDROME – ScienceDirect”.
- ↑ Falorni A, Minarelli V, Bartoloni E, Alunno A, Gerli R (2014). “Diagnosis and classification of autoimmune hypophysitis”. Autoimmun Rev. 13 (4–5): 412–6. doi:10.1016/j.autrev.2014.01.021. PMID 24434361.
- ↑ Carvalho LR, Woods KS, Mendonca BB, Marcal N, Zamparini AL, Stifani S, Brickman JM, Arnhold IJ, Dattani MT (2003). “A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction”. J. Clin. Invest. 112 (8): 1192–201. doi:10.1172/JCI18589. PMC 213489. PMID 14561704.
- ↑ Sobrier ML, Maghnie M, Vié-Luton MP, Secco A, di Iorgi N, Lorini R, Amselem S (2006). “Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities”. J. Clin. Endocrinol. Metab. 91 (11): 4528–36. doi:10.1210/jc.2006-0426. PMID 16940453.
- ↑ Netchine I, Sobrier ML, Krude H, Schnabel D, Maghnie M, Marcos E, Duriez B, Cacheux V, Moers A, Goossens M, Grüters A, Amselem S (2000). “Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency”. Nat. Genet. 25 (2): 182–6. doi:10.1038/76041. PMID 10835633. Vancouver style error: initials (help)
- ↑ Machinis K, Pantel J, Netchine I, Léger J, Camand OJ, Sobrier ML, Dastot-Le Moal F, Duquesnoy P, Abitbol M, Czernichow P, Amselem S (2001). “Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4”. Am. J. Hum. Genet. 69 (5): 961–8. PMC 1274372. PMID 11567216.
- ↑ Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O’Connell SM, Flynn SE, Brown MR, Mullis PE, Parks JS, Phillips JA, Rosenfeld MG (1998). “Mutations in PROP1 cause familial combined pituitary hormone deficiency”. Nat. Genet. 18 (2): 147–9. doi:10.1038/ng0298-147. PMID 9462743.
- ↑ Pellegrini-Bouiller I, Bélicar P, Barlier A, Gunz G, Charvet JP, Jaquet P, Brue T, Vialettes B, Enjalbert A (1996). “A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency”. J. Clin. Endocrinol. Metab. 81 (8): 2790–6. doi:10.1210/jcem.81.8.8768831. PMID 8768831.
- ↑ Pfäffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, Van der Nat H, Van den Brande JL, Rosenfeld MG, Ingraham HA (1992). “Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia”. Science. 257 (5073): 1118–21. PMID 1509263.
- ↑ Turton JP, Reynaud R, Mehta A, Torpiano J, Saveanu A, Woods KS, Tiulpakov A, Zdravkovic V, Hamilton J, Attard-Montalto S, Parascandalo R, Vella C, Clayton PE, Shalet S, Barton J, Brue T, Dattani MT (2005). “Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency”. J. Clin. Endocrinol. Metab. 90 (8): 4762–70. doi:10.1210/jc.2005-0570. PMID 15928241.
- ↑ Bhangoo AP, Hunter CS, Savage JJ, Anhalt H, Pavlakis S, Walvoord EC, Ten S, Rhodes SJ (2006). “Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency”. J. Clin. Endocrinol. Metab. 91 (3): 747–53. doi:10.1210/jc.2005-2360. PMID 16394081.
- ↑ Cogan JD, Wu W, Phillips JA, Arnhold IJ, Agapito A, Fofanova OV, Osorio MG, Bircan I, Moreno A, Mendonca BB (1998). “The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency”. J. Clin. Endocrinol. Metab. 83 (9): 3346–9. doi:10.1210/jcem.83.9.5142. PMID 9745452.
- ↑ Flück C, Deladoey J, Rutishauser K, Eblé A, Marti U, Wu W, Mullis PE (1998). “Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg–>Cys at codon 120 (R120C)”. J. Clin. Endocrinol. Metab. 83 (10): 3727–34. doi:10.1210/jcem.83.10.5172. PMID 9768691.
- ↑ Rosenbloom AL, Almonte AS, Brown MR, Fisher DA, Baumbach L, Parks JS (1999). “Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of the PROP1 gene”. J. Clin. Endocrinol. Metab. 84 (1): 50–7. doi:10.1210/jcem.84.1.5366. PMID 9920061.
- ↑ Pernasetti F, Toledo SP, Vasilyev VV, Hayashida CY, Cogan JD, Ferrari C, Lourenço DM, Mellon PL (2000). “Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene”. J. Clin. Endocrinol. Metab. 85 (1): 390–7. doi:10.1210/jcem.85.1.6324. PMID 10634415.
- ↑ Lee JK, Zhu YS, Cordero JJ, Cai LQ, Labour I, Herrera C, Imperato-McGinley J (2004). “Long-term growth hormone therapy in adulthood results in significant linear growth in siblings with a PROP-1 gene mutation”. J. Clin. Endocrinol. Metab. 89 (10): 4850–6. doi:10.1210/jc.2003-031816. PMID 15472175.
- ↑ Yamamoto M, Iguchi G, Takeno R, Okimura Y, Sano T, Takahashi M, Nishizawa H, Handayaningshi AE, Fukuoka H, Tobita M, Saitoh T, Tojo K, Mokubo A, Morinobu A, Iida K, Kaji H, Seino S, Chihara K, Takahashi Y (2011). “Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans”. J. Clin. Invest. 121 (1): 113–9. doi:10.1172/JCI44073. PMC 3007153. PMID 21123951.
- ↑ Vallette-Kasic S, Brue T, Pulichino AM, Gueydan M, Barlier A, David M, Nicolino M, Malpuech G, Déchelotte P, Deal C, Van Vliet G, De Vroede M, Riepe FG, Partsch CJ, Sippell WG, Berberoglu M, Atasay B, de Zegher F, Beckers D, Kyllo J, Donohoue P, Fassnacht M, Hahner S, Allolio B, Noordam C, Dunkel L, Hero M, Pigeon B, Weill J, Yigit S, Brauner R, Heinrich JJ, Cummings E, Riddell C, Enjalbert A, Drouin J (2005). “Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations”. J. Clin. Endocrinol. Metab. 90 (3): 1323–31. doi:10.1210/jc.2004-1300. PMID 15613420.
- ↑ Yang Y, Guo QH, Wang BA, Dou JT, Lv ZH, Ba JM, Lu JM, Pan CY, Mu YM (2013). “Pituitary stalk interruption syndrome in 58 Chinese patients: clinical features and genetic analysis”. Clin. Endocrinol. (Oxf). 79 (1): 86–92. doi:10.1111/cen.12116. PMID 23199197.
- ↑ Wang W, Wang S, Jiang Y, Yan F, Su T, Zhou W, Jiang L, Zhang Y, Ning G (2015). “Relationship between pituitary stalk (PS) visibility and the severity of hormone deficiencies: PS interruption syndrome revisited”. Clin. Endocrinol. (Oxf). 83 (3): 369–76. doi:10.1111/cen.12788. PMID 25845766.
- ↑ Mendonca BB, Osorio MG, Latronico AC, Estefan V, Lo LS, Arnhold IJ (1999). “Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene”. J. Clin. Endocrinol. Metab. 84 (3): 942–5. doi:10.1210/jcem.84.3.5537. PMID 10084575.
- ↑ De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A (2005). “Primary empty sella”. J. Clin. Endocrinol. Metab. 90 (9): 5471–7. doi:10.1210/jc.2005-0288. PMID 15972577.
- ↑ <http://creativecommons.org/licenses/by-sa/3.0>, via Wikimedia Common
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]
Overview
Causes of hypopituitarism can be classified based upon the etiology into congenital or acquired. Common congenital causes include idiopathic, anatomic lesion in the sella turcica and CNS malformations. Common acquired causes may include pituitary macroadenoma, craniopharyngioma, surgery, radiation, traumatic brain injury, Sheehan’s syndrome, apoplexy, SAH, meningitis, hypophysitis, meningioma, lymphoma, hemochromatosis and Wegner’s granulomatosis. Less common causes include Peri-natal insults, genetic causes, such as Kallman syndrome, Pallister-Hall syndrome, Rieger syndrome, and pituitary hypoplasia or aplasia.
Common Causes
Causes can be classified based upon the etiology into congenital or acquired. The most common cause is a pituitary tumor. Other possible causes may include cyst or a tumor in hypothalamus or infundibulum, vascular disorders, infiltrative diseases, genetic disorders, radiation, and surgery.
| Etiology | Underlying cause/disease |
|---|---|
| Congeital | Idiopathic |
| Anatomic lesion in sella turcica: Rathke’s cyst | |
| CNS malformations: septo-optic–dysplasia, Kallmann syndrome, and pituitary stalk interruption syndrome | |
| Acquired | Pituitary tumor: mainly displacing macroadenoma (non-functioning or functioning adenomas) |
| Posterior pituitary tumor: astrocytoma, ganglioneuroma | |
| Metastatic: breast, lungs, colon, prostate | |
| Peripituitary lesions: Craniopharyngioma, meningioma, chordoma, optic nerve glioma | |
| Surgery: Transsphenoidal or transcranial surgery in the hypothalamo-pituitary region | |
| Radiation | |
| Systemic cancer treatment | |
| Traumatic brain injury | |
| Sheehan’s syndrome | |
| Pituitary apoplexy | |
| Meningitis | |
| Hypophysitis | |
| Lymphoma |
Less common causes:
Less common causes of hypopituitarism include:[1][2][3][4][5][6][7][8][9][10][11][12][13][14]
- Perinatal insults
- Genetic causes involving isolated/multiple pituitary hormone deficits (MPHD) such as Kallman syndrome, Pallister-Hall syndrome, and Rieger syndrome. To see a complete list of genetic causes, click here.
- Head trauma
- Pituitary hypoplasia or aplasia
- Empty sella syndrome
- Infiltrative diseases
- Ischemic stroke
- Subarachnoid hemorrhage
- Internal carotid artery aneurysm
Causes by Organ System
| Cardiovascular | Congestive heart failure, arteriosclerosis, arteritis temporalis, eclampsia, intracranial cartoid branch aneurysm |
| Chemical/Poisoning | No underlying causes |
| Dental | No underlying causes |
| Dermatologic | No underlying causes |
| Drug Side Effect | Anticoagulant therapy |
| Ear Nose Throat | No underlying causes |
| Endocrine | Empty sella syndrome, diabetes mellitus, Sheehan’s Syndrome, pituitary apoplexy |
| Environmental | No underlying causes |
| Gastroenterologic | No underlying causes |
| Genetic | Hemochromatosis, Genetic mutations: GHRHR, GH1, TSHB, TRHR, TPIT, GnRHR, PC1, POMC, DAX1, CRH, KAL1, FGFR1, leptin, leptin-R, GPR54, Kisspeptin, FSHB, LHB, PROK2, PROKR2, AVP-NPII, POU1F1, PROP1, HESX1, LHX3, LHX4, SOX3, GLI2, SOX2, GLI3, PITX2 |
| Hematologic | Blood dyscrasias, sickle cell anemia |
| Iatrogenic | Radiation, surgery |
| Infectious Disease | Fungal, malaria, meningitis, syphillis, tuberculosis |
| Musculoskeletal/Orthopedic | No underlying causes |
| Neurologic | Stroke |
| Nutritional/Metabolic | No underlying causes |
| Obstetric/Gynecologic | Peri-natal insults |
| Oncologic | Brain tumor, meningioma, craniopharyngioma, metastasis, optic nerve neuroma, lymphoma |
| Ophthalmologic | No underlying causes |
| Overdose/Toxicity | No underlying causes |
| Psychiatric | Anorexia nervosa, bulimia nervosa |
| Pulmonary | Sarcoidosis |
| Renal/Electrolyte | Renal failure |
| Rheumatology/Immunology/Allergy | Wegener’s granulomatosis |
| Sexual | No underlying causes |
| Trauma | Head trauma |
| Urologic | No underlying causes |
| Miscellaneous | Infiltrative lesions (sarcoidosis, Langerhans cell histiocytosis, hypophysitis, hemochromatosis) |
Causes in Alphabetical Order
- Arteriosclerosis
- Arteritis temporalis
- Blood dyscrasias
- Congestive Heart Failure
- Diabetes Mellitus
- Empty Sella Syndrome
- Idiopathic
- Infections
- Infiltrative lesions
- Internal carotid artery aneurysm
- Pituitary apoplexy
- Radiation
- Renal Failure
- Sheehan’s Syndrome
- Surgery
- Trauma
- Tumors
- Wegener’s Granulomatosis
Etiology based on anatomical location of pathology:
Hypopituitarism can be classified based upon the anatomical location of pathology such as hypothalamus or pituitary gland.[15][16][17][18][19][20][21][22][3][10][23][9][12][24][25][26][27][8][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43]
| Anatomical location | Cause |
|---|---|
| Hypothalmic | Mass lesions:
|
| Radiation : CNS and nasopharyngeal malignancies | |
| Infections: Tuberculous meningitis | |
| Infiltrative lesions: | |
| Other : | |
| Pituitary | Mass lesions: |
| Pituitary radiation | |
| Pituitary surgery | |
| Infection or abscess | |
| Infiltrative lesions:
1. Hypophysitis:
| |
| Infarction: Sheehan’s syndrome | |
| Apoplexy | |
| Empty sella | |
| Genetic mutations |
Genetic Causes
Hypopituitarism is caused by mutation in any one of the following genes.[44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63]
| Isolated
hormone abnormalities |
Gene | Inheritance | Phenotype |
|---|---|---|---|
| GH1 | AR, AD | Isolated GH deficiency | |
| GHRHR | AR | Isolated GH deficiency | |
| TSHB | AR | Isolated TSH deficiency | |
| TRHR | AR | Isolated TSH deficiency | |
| TPIT | AR | Isolated ACTH deficiency | |
| GnRHR | AR | HH | |
| PC1 | AR | ACTH deficiency, hypoglycemia, HH, obesity | |
| POMC | AR | ACTH deficiency, obesity, red hair | |
| DAX1 | XL | Adrenal hypoplasia congenital and HH | |
| CRH | AR | CRH deficiency | |
| KAL1 | XL | Kallman syndrome, renal agenesis, synkinesia | |
| FGFR1 | AD, AR | Kallman syndrome, cleft lip and palate, facial dysmorphism | |
| Leptin | AR | HH, obesity | |
| Leptin-R | AR | HH, obesity | |
| GPR54 | AR | HH | |
| Kisspeptin | AR | HH | |
| FSHB | AR | Primary amenorrhea, defective spermatogenesis | |
| LHB | AR | Delayed puberty | |
| PROK2 | AD | Kallman syndrome, severe sleep disorder, obesity | |
| PROKR2 | AD, AR | Kallman syndrome | |
| AVP-NPII | AR, AD | Diabetes insipidus | |
| Combined pituitary hormone deficiency | POU1F1 | AR, AD | GH, TSH, and prolactin deficiencies |
| PROP1 | AR | GH, TSH, LH, FSH, prolactin, and evolving ACTH deficiencies | |
| Specific syndromes | HESX1 | AR, AD | Septo-optic dysplasia |
| LHX3 | AR | GH, TSH, LH, FSH, prolactin deficiencies, limited neck rotation | |
| LHX4 | AD | GH, TSH, ACTH deficiencies with cerebellar abnormalities | |
| SOX3 | XL | Hypopituitarism and mental retardation | |
| GLI2 | AD | Holoprosencephaly and multiple midline defects | |
| SOX2 | AD | Anophthalmia, hypopituitarism, oesophageal atresia | |
| GLI3 | AD | Pallister-Hall syndrome | |
| PITX2 | AD | Rieger syndrome |
References
- ↑ “Pituitary insufficiency – ScienceDirect”.
- ↑ Eiholzer U, Zachmann M, Gnehm HE, Prader A (1986). “Recovery from post-traumatic anterior pituitary insufficiency”. Eur. J. Pediatr. 145 (1–2): 128–30. PMID 3089793.
- ↑ 3.0 3.1 Edwards OM, Clark JD (1986). “Post-traumatic hypopituitarism. Six cases and a review of the literature”. Medicine (Baltimore). 65 (5): 281–90. PMID 3018425.
- ↑ Ishikawa S, Furuse M, Saito T, Okada K, Kuzuya T (1988). “Empty sella in control subjects and patients with hypopituitarism”. Endocrinol. Jpn. 35 (5): 665–74. PMID 3220045.
- ↑ Nakagawa Y, Matsumoto K, Fukami T, Takase K (1984). “Exploration of the pituitary stalk and gland by high-resolution computed tomography. Comparative study of normal subjects and cases with microadenoma”. Neuroradiology. 26 (6): 473–8. PMID 6504317.
- ↑ Asa SL, Bilbao JM, Kovacs K, Josse RG, Kreines K (1981). “Lymphocytic hypophysitis of pregnancy resulting in hypopituitarism: a distinct clinicopathologic entity”. Ann. Intern. Med. 95 (2): 166–71. PMID 7196190.
- ↑ Miura M, Ushio Y, Kuratsu J, Ikeda J, Kai Y, Yamashiro S (1989). “Lymphocytic adenohypophysitis: report of two cases”. Surg Neurol. 32 (6): 463–70. PMID 2700055.
- ↑ 8.0 8.1 Kelly TM, Edwards CQ, Meikle AW, Kushner JP (1984). “Hypogonadism in hemochromatosis: reversal with iron depletion”. Ann. Intern. Med. 101 (5): 629–32. PMID 6435491.
- ↑ 9.0 9.1 Bondanelli M, Ambrosio MR, Carli A, Bergonzoni A, Bertocchi A, Zatelli MC, Ceruti S, Valle D, Basaglia N, degli Uberti EC (2010). “Predictors of pituitary dysfunction in patients surviving ischemic stroke”. J. Clin. Endocrinol. Metab. 95 (10): 4660–8. doi:10.1210/jc.2010-0611. PMID 20660027.
- ↑ 10.0 10.1 Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E (2007). “Hypopituitarism”. Lancet. 369 (9571): 1461–70. doi:10.1016/S0140-6736(07)60673-4. PMID 17467517.
- ↑ Klose M, Brennum J, Poulsgaard L, Kosteljanetz M, Wagner A, Feldt-Rasmussen U (2010). “Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage”. Clin. Endocrinol. (Oxf). 73 (1): 95–101. doi:10.1111/j.1365-2265.2010.03791.x. PMID 20105184.
- ↑ 12.0 12.1 Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A (2007). “Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review”. JAMA. 298 (12): 1429–38. doi:10.1001/jama.298.12.1429. PMID 17895459.
- ↑ Hannon MJ, Behan LA, O’Brien MM, Tormey W, Javadpour M, Sherlock M, Thompson CJ (2015). “Chronic hypopituitarism is uncommon in survivors of aneurysmal subarachnoid haemorrhage”. Clin. Endocrinol. (Oxf). 82 (1): 115–21. doi:10.1111/cen.12533. PMID 24965315.
- ↑ Ooi TC, Russell NA (1986). “Hypopituitarism resulting from an intrasellar carotid aneurysm”. Can J Neurol Sci. 13 (1): 70–1. PMID 3955456.
- ↑ Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, Rubin P (1993). “Hypothalamic-pituitary dysfunction after radiation for brain tumors”. N. Engl. J. Med. 328 (2): 87–94. doi:10.1056/NEJM199301143280203. PMID 8416438.
- ↑ Lam KS, Wang C, Yeung RT, Ma JT, Ho JH, Tse VK, Ling N (1986). “Hypothalamic hypopituitarism following cranial irradiation for nasopharyngeal carcinoma”. Clin. Endocrinol. (Oxf). 24 (6): 643–51. PMID 3098456.
- ↑ Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, Neelis KJ, Biermasz NR, Romijn JA, Smit JW, Pereira AM (2011). “Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis”. J. Clin. Endocrinol. Metab. 96 (8): 2330–40. doi:10.1210/jc.2011-0306. PMC 3146793. PMID 21613351.
- ↑ Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, Monson JP, Besser GM, Grossman AB (2000). “Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment”. J. Clin. Endocrinol. Metab. 85 (4): 1370–6. doi:10.1210/jcem.85.4.6501. PMID 10770168.
- ↑ Imashuku S, Kudo N, Kaneda S, Kuroda H, Shiwa T, Hiraiwa T, Inagaki A, Morimoto A (2011). “Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis”. Int. J. Hematol. 94 (6): 556–60. doi:10.1007/s12185-011-0955-z. PMID 22015494.
- ↑ Lam KS, Sham MM, Tam SC, Ng MM, Ma HT (1993). “Hypopituitarism after tuberculous meningitis in childhood”. Ann. Intern. Med. 118 (9): 701–6. PMID 8460856.
- ↑ Morichika D, Sato-Hisamoto A, Hotta K, Takata K, Iwaki N, Uchida K, Minami D, Kubo T, Tanimoto M, Kiura K (2014). “Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: a case report”. Jpn. J. Clin. Oncol. 44 (5): 501–5. doi:10.1093/jjco/hyu019. PMID 24646812.
- ↑ Harbeck B, Klose S, Buchfelder M, Brabant G, Lehnert H (2011). “Hypopituitarism in a HIV affected patient”. Exp. Clin. Endocrinol. Diabetes. 119 (10): 633–5. doi:10.1055/s-0031-1284366. PMID 21922454.
- ↑ Agha A, Thornton E, O’Kelly P, Tormey W, Phillips J, Thompson CJ (2004). “Posterior pituitary dysfunction after traumatic brain injury”. J. Clin. Endocrinol. Metab. 89 (12): 5987–92. doi:10.1210/jc.2004-1058. PMID 15579748.
- ↑ Kronvall E, Valdemarsson S, Säveland H, Nilsson OG (2015). “High prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a long-term prospective study using dynamic endocrine testing”. World Neurosurg. 83 (4): 574–82. doi:10.1016/j.wneu.2014.12.007. PMID 25514615.
- ↑ Jahangiri A, Wagner JR, Han SW, Tran MT, Miller LM, Chen R, Tom MW, Ostling LR, Kunwar S, Blevins L, Aghi MK (2016). “Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis”. J. Neurosurg. 124 (3): 589–95. doi:10.3171/2015.1.JNS141543. PMID 26252454.
- ↑ Snyder PJ, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA (1986). “Hypopituitarism following radiation therapy of pituitary adenomas”. Am. J. Med. 81 (3): 457–62. PMID 3092668.
- ↑ Eastman RC, Gorden P, Roth J (1979). “Conventional supervoltage irradiation is an effective treatment for acromegaly”. J. Clin. Endocrinol. Metab. 48 (6): 931–40. doi:10.1210/jcem-48-6-931. PMID 447799.
- ↑ Leporati P, Landek-Salgado MA, Lupi I, Chiovato L, Caturegli P (2011). “IgG4-related hypophysitis: a new addition to the hypophysitis spectrum”. J. Clin. Endocrinol. Metab. 96 (7): 1971–80. doi:10.1210/jc.2010-2970. PMC 3135201. PMID 21593109.
- ↑ Cheung CC, Ezzat S, Smyth HS, Asa SL (2001). “The spectrum and significance of primary hypophysitis”. J. Clin. Endocrinol. Metab. 86 (3): 1048–53. doi:10.1210/jcem.86.3.7265. PMID 11238484.
- ↑ Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S (1995). “Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings”. J. Clin. Endocrinol. Metab. 80 (8): 2302–11. doi:10.1210/jcem.80.8.7629223. PMID 7629223.
- ↑ Cosman F, Post KD, Holub DA, Wardlaw SL (1989). “Lymphocytic hypophysitis. Report of 3 new cases and review of the literature”. Medicine (Baltimore). 68 (4): 240–56. PMID 2661963.
- ↑ Honegger J, Schlaffer S, Menzel C, Droste M, Werner S, Elbelt U, Strasburger C, Störmann S, Küppers A, Streetz-van der Werf C, Deutschbein T, Stieg M, Rotermund R, Milian M, Petersenn S (2015). “Diagnosis of Primary Hypophysitis in Germany”. J. Clin. Endocrinol. Metab. 100 (10): 3841–9. doi:10.1210/jc.2015-2152. PMID 26262437.
- ↑ Kristof RA, Van Roost D, Klingmüller D, Springer W, Schramm J (1999). “Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy?”. J. Neurol. Neurosurg. Psychiatr. 67 (3): 398–402. PMC 1736542. PMID 10449568.
- ↑ Chico A, Puig-Domingo M, Martul P, De Juan M, Prats JM, Mauricio D, Webb SM (1998). “Reversible endocrine dysfunction and pituitary stalk enlargement”. J. Endocrinol. Invest. 21 (2): 122–7. doi:10.1007/BF03350326. PMID 9585387.
- ↑ Tebben PJ, Atkinson JL, Scheithauer BW, Erickson D (2007). “Granulomatous adenohypophysitis after interferon and ribavirin therapy”. Endocr Pract. 13 (2): 169–75. doi:10.4158/EP.13.2.169. PMID 17490932.
- ↑ Bando H, Iguchi G, Fukuoka H, Taniguchi M, Yamamoto M, Matsumoto R, Suda K, Nishizawa H, Takahashi M, Kohmura E, Takahashi Y (2014). “The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature”. Eur. J. Endocrinol. 170 (2): 161–72. doi:10.1530/EJE-13-0642. PMID 24165017.
- ↑ Barkan AL (1989). “Pituitary atrophy in patients with Sheehan’s syndrome”. Am. J. Med. Sci. 298 (1): 38–40. PMID 2750772.
- ↑ Keleştimur F (2003). “Sheehan’s syndrome”. Pituitary. 6 (4): 181–8. PMID 15237929.
- ↑ Zargar AH, Singh B, Laway BA, Masoodi SR, Wani AI, Bashir MI (2005). “Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan’s syndrome)”. Fertil. Steril. 84 (2): 523–8. doi:10.1016/j.fertnstert.2005.02.022. PMID 16084902.
- ↑ Diri H, Tanriverdi F, Karaca Z, Senol S, Unluhizarci K, Durak AC, Atmaca H, Kelestimur F (2014). “Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder”. Eur. J. Endocrinol. 171 (3): 311–8. doi:10.1530/EJE-14-0244. PMID 24917653.
- ↑ Vargas G, Gonzalez B, Guinto G, Mendoza V, López-Félix B, Zepeda E, Mercado M (2014). “Pituitary apoplexy in nonfunctioning pituitary macroadenomas: a case-control study”. Endocr Pract. 20 (12): 1274–80. doi:10.4158/EP14120.OR. PMID 25100377.
- ↑ Capatina C, Inder W, Karavitaki N, Wass JA (2015). “Management of endocrine disease: pituitary tumour apoplexy”. Eur. J. Endocrinol. 172 (5): R179–90. doi:10.1530/EJE-14-0794. PMID 25452466.
- ↑ Dalan R, Leow MK (2008). “Pituitary abscess: our experience with a case and a review of the literature”. Pituitary. 11 (3): 299–306. doi:10.1007/s11102-007-0057-3. PMID 17594523.
- ↑ Carvalho LR, Woods KS, Mendonca BB, Marcal N, Zamparini AL, Stifani S, Brickman JM, Arnhold IJ, Dattani MT (2003). “A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction”. J. Clin. Invest. 112 (8): 1192–201. doi:10.1172/JCI18589. PMC 213489. PMID 14561704.
- ↑ Sobrier ML, Maghnie M, Vié-Luton MP, Secco A, di Iorgi N, Lorini R, Amselem S (2006). “Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities”. J. Clin. Endocrinol. Metab. 91 (11): 4528–36. doi:10.1210/jc.2006-0426. PMID 16940453.
- ↑ Netchine I, Sobrier ML, Krude H, Schnabel D, Maghnie M, Marcos E, Duriez B, Cacheux V, Moers A, Goossens M, Grüters A, Amselem S (2000). “Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency”. Nat. Genet. 25 (2): 182–6. doi:10.1038/76041. PMID 10835633. Vancouver style error: initials (help)
- ↑ Machinis K, Pantel J, Netchine I, Léger J, Camand OJ, Sobrier ML, Dastot-Le Moal F, Duquesnoy P, Abitbol M, Czernichow P, Amselem S (2001). “Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4”. Am. J. Hum. Genet. 69 (5): 961–8. PMC 1274372. PMID 11567216.
- ↑ Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O’Connell SM, Flynn SE, Brown MR, Mullis PE, Parks JS, Phillips JA, Rosenfeld MG (1998). “Mutations in PROP1 cause familial combined pituitary hormone deficiency”. Nat. Genet. 18 (2): 147–9. doi:10.1038/ng0298-147. PMID 9462743.
- ↑ Pellegrini-Bouiller I, Bélicar P, Barlier A, Gunz G, Charvet JP, Jaquet P, Brue T, Vialettes B, Enjalbert A (1996). “A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency”. J. Clin. Endocrinol. Metab. 81 (8): 2790–6. doi:10.1210/jcem.81.8.8768831. PMID 8768831.
- ↑ Pfäffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, Van der Nat H, Van den Brande JL, Rosenfeld MG, Ingraham HA (1992). “Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia”. Science. 257 (5073): 1118–21. PMID 1509263.
- ↑ Turton JP, Reynaud R, Mehta A, Torpiano J, Saveanu A, Woods KS, Tiulpakov A, Zdravkovic V, Hamilton J, Attard-Montalto S, Parascandalo R, Vella C, Clayton PE, Shalet S, Barton J, Brue T, Dattani MT (2005). “Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency”. J. Clin. Endocrinol. Metab. 90 (8): 4762–70. doi:10.1210/jc.2005-0570. PMID 15928241.
- ↑ Bhangoo AP, Hunter CS, Savage JJ, Anhalt H, Pavlakis S, Walvoord EC, Ten S, Rhodes SJ (2006). “Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency”. J. Clin. Endocrinol. Metab. 91 (3): 747–53. doi:10.1210/jc.2005-2360. PMID 16394081.
- ↑ Cogan JD, Wu W, Phillips JA, Arnhold IJ, Agapito A, Fofanova OV, Osorio MG, Bircan I, Moreno A, Mendonca BB (1998). “The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency”. J. Clin. Endocrinol. Metab. 83 (9): 3346–9. doi:10.1210/jcem.83.9.5142. PMID 9745452.
- ↑ Flück C, Deladoey J, Rutishauser K, Eblé A, Marti U, Wu W, Mullis PE (1998). “Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg–>Cys at codon 120 (R120C)”. J. Clin. Endocrinol. Metab. 83 (10): 3727–34. doi:10.1210/jcem.83.10.5172. PMID 9768691.
- ↑ Rosenbloom AL, Almonte AS, Brown MR, Fisher DA, Baumbach L, Parks JS (1999). “Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of the PROP1 gene”. J. Clin. Endocrinol. Metab. 84 (1): 50–7. doi:10.1210/jcem.84.1.5366. PMID 9920061.
- ↑ Pernasetti F, Toledo SP, Vasilyev VV, Hayashida CY, Cogan JD, Ferrari C, Lourenço DM, Mellon PL (2000). “Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene”. J. Clin. Endocrinol. Metab. 85 (1): 390–7. doi:10.1210/jcem.85.1.6324. PMID 10634415.
- ↑ Lee JK, Zhu YS, Cordero JJ, Cai LQ, Labour I, Herrera C, Imperato-McGinley J (2004). “Long-term growth hormone therapy in adulthood results in significant linear growth in siblings with a PROP-1 gene mutation”. J. Clin. Endocrinol. Metab. 89 (10): 4850–6. doi:10.1210/jc.2003-031816. PMID 15472175.
- ↑ Yamamoto M, Iguchi G, Takeno R, Okimura Y, Sano T, Takahashi M, Nishizawa H, Handayaningshi AE, Fukuoka H, Tobita M, Saitoh T, Tojo K, Mokubo A, Morinobu A, Iida K, Kaji H, Seino S, Chihara K, Takahashi Y (2011). “Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans”. J. Clin. Invest. 121 (1): 113–9. doi:10.1172/JCI44073. PMC 3007153. PMID 21123951.
- ↑ Vallette-Kasic S, Brue T, Pulichino AM, Gueydan M, Barlier A, David M, Nicolino M, Malpuech G, Déchelotte P, Deal C, Van Vliet G, De Vroede M, Riepe FG, Partsch CJ, Sippell WG, Berberoglu M, Atasay B, de Zegher F, Beckers D, Kyllo J, Donohoue P, Fassnacht M, Hahner S, Allolio B, Noordam C, Dunkel L, Hero M, Pigeon B, Weill J, Yigit S, Brauner R, Heinrich JJ, Cummings E, Riddell C, Enjalbert A, Drouin J (2005). “Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations”. J. Clin. Endocrinol. Metab. 90 (3): 1323–31. doi:10.1210/jc.2004-1300. PMID 15613420.
- ↑ Yang Y, Guo QH, Wang BA, Dou JT, Lv ZH, Ba JM, Lu JM, Pan CY, Mu YM (2013). “Pituitary stalk interruption syndrome in 58 Chinese patients: clinical features and genetic analysis”. Clin. Endocrinol. (Oxf). 79 (1): 86–92. doi:10.1111/cen.12116. PMID 23199197.
- ↑ Wang W, Wang S, Jiang Y, Yan F, Su T, Zhou W, Jiang L, Zhang Y, Ning G (2015). “Relationship between pituitary stalk (PS) visibility and the severity of hormone deficiencies: PS interruption syndrome revisited”. Clin. Endocrinol. (Oxf). 83 (3): 369–76. doi:10.1111/cen.12788. PMID 25845766.
- ↑ Mendonca BB, Osorio MG, Latronico AC, Estefan V, Lo LS, Arnhold IJ (1999). “Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene”. J. Clin. Endocrinol. Metab. 84 (3): 942–5. doi:10.1210/jcem.84.3.5537. PMID 10084575.
- ↑ De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A (2005). “Primary empty sella”. J. Clin. Endocrinol. Metab. 90 (9): 5471–7. doi:10.1210/jc.2005-0288. PMID 15972577.
Differentiating Hypopituitarism from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2], Ahmed Elsaiey, MBBCH [3]
Overview
Hypopituitarism should be differentiated from other diseases causing panhypopituitarism, hypothyroidism, hypogonadism, ACTH deficiency, GH deficiency, ADH deficiency and high prolactin level.
Differentiating Hypopituitarism From Other Diseases
- For the differential of hypopituitarism on the basis of thyroid hormone deficiency, click here.
- For the differential of hypopituitarism on the basis of panhypopituitarism, click here.
- For the differential of hypopituitarism on the basis of gonadotropins (FSH/LH) deficiency, click here.
- For the differential of hypopituitarism on the basis of high prolactin level, click here.
- For the differential of hypopituitarism on the basis of growth hormone deficiency, click here.
- For the differential of hypopituitarism on the basis of ADH deficiency, click here.
Differentiating various causes of Panhypopituitarism
Hypopituitarism should be differentiated from other diseases causing panhypopituitarism, hypothyroidism, hypogonadism, ACTH deficiency, GH deficiency, ADH deficiency and high prolactin level.[1][2][3][4][5][6][7]
| Diseases | Onset | Manifestations | Diagnosis | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| History and Symptoms | Physical examination | Laboratory findings | Gold standard | Imaging | Other investigation findings | |||||
| Trumatic delivery | Lactation failure | Menstrual irregularities | Other features | |||||||
| Panhypopituitarism | Chronic | – | + | Oligo/amenorrhea |
|
|
|
| ||
| Sheehan’s syndrome | Acute | ++ | ++ | Oligo/amenorrhea |
|
|
|
CT/MRI:
|
| |
| Lymphocytic hypophysitis | Acute | +/- | + | Oligo/amenorrhea |
|
|
|
Assays for:
| ||
| Pituitary apoplexy | Acute | +/- | ++ | Oligo/amenorrhea | Severe headache
|
|
|
Blood tests may be done to check: | ||
| Empty sella syndrome | Chronic | – | + | Oligo/amenorrhea |
|
|
|
|
| |
| Simmond’s disease/Pituitary cachexia | Chronic | +/- | + | Oligo/amenorrhea |
|
|
| |||
Differentiating hypopituitarism from hypothyroidism that present as a single hormonal deficiency
| Disease | History and symptoms | Laboratory findings | Additional findings | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fever | Goiter | Pain | TSH | Free T4 | T3 | T3RU | Thyroglobin | TRH | TPOAb | |||
| Primary hypothyroidism | Autoimmune | + | +/-
Diffuse |
– | ↑ | ↓ | N/↓ | Normal | N/↑ | Normal | ↑ |
|
| Thyroiditis | + | +/- | + | ↑ | ↓ | Normal | Normal | N/↑ | Normal | Normal |
| |
| Others | – | +/- | – | ↑ | ↓ | Normal | Normal | N/↑ | Normal | Normal |
| |
| Transient hypothyroidism | +/- | – | +/- | ↑ | ↑ | Normal | Normal | ↑ | Normal | Normal |
| |
| Subclinical hypothyroidism | – | – | – | ↑ | Normal | Normal | Normal | ↑ | Normal | N/↑ |
| |
| Central Hypothyroidism | Pituitary | + | – | – | N/↓ | N/↓ | N/↓ | ↓ | Normal | Normal | Normal |
|
| Hypothalamus | + | – | – | ↓ | Normal | ↓ | Normal |
| ||||
| Resistance to TSH/TRH | – | – | – | ↑ | N/↓ | N/↓ | Normal | Normal | ↑/↓ | Normal |
| |
Legend:’TSH: Thyroid stimulating hormone, T4: Teraiodothyronine, T3: Triiodothyronine, T3RU: Triiodothyronine reuptake, TRH: Thyrotrophin releasing hormone, TPOAb: Thyroid peroxidase antibody, N: Normal, +: Present, -: Absent
Differentiating hypopituitarism on the basis of Gonadotropins (FSH/LH) deficiency
[12][13][14][15][16][17][18][19][20][21]
| Diseases | Clinical findings | Diagnosis | Manangement | |
|---|---|---|---|---|
| Congenital diseases | Klinefelter syndrome | Clinical features of Klinefelter syndrome are as the following:[12]
|
|
|
| Kallmann syndrome | Clinical features of Kallmann syndrome include:
|
| ||
Differentiating hypopituitarism on the basis of High prolactin level
[22][23][24][25][26][27][28][29][30]
| Disease | Clinical Findings | Laboratory findings | Management |
|---|---|---|---|
| Somatotroph adenoma: | Clinical features of acromegaly are due to high level of human growth hormone (hGH):
|
|
|
| Corticotroph adenoma: Cushing’s syndrome | Clinical features of Cushing’s syndrome are due to increased levels of cortisol:
|
|
|
| Hypothyroidism | Clinical features of hypothyroidism are due to deficiency of thyroxine:
|
|
Levothyroxine |
| Chronic renal failure | There are no pathognomonic symptoms associated with chronic renal failure. Common non-specific symptoms of chronic renal failure include:
|
Urinalysis:
Fluid and electrolyte disturbances: Endocrine and metabolic disturbances:
Hematologic abnormalities: |
|
| Liver disease: Cirrhosis | The clinical features of liver cirrhosis are very nonspecific. These include:
|
|
|
| Seizure disorder | The clinical features of seizure disorder may include:
|
Electroencephalogram |
|
| Medication-induced | Clinical features of hyperprolactinemia after a specific period of regular medication ingestion | Discontinuation of the medication for 3 days and remeasurement of prolactin levels[31] | Change to alternate medication |
Differentiating hypopituitarism on the basis of GH Deficiency
| Diseases | History and symptoms | Physical Examination | Laboratory findings | |||||
|---|---|---|---|---|---|---|---|---|
| Puberty development | Height velocity | Parents height | Characteristic facies | Bone age | Genetic analysis | GH level | ||
| Growth hormone deficiency[32] |
|
Delayed | Decreased | Normal |
|
Dlayed |
|
Low |
| Achondroplasia[33] |
|
Normal | Decreased | Decreased |
|
Delayed |
FGFR3 gene mutations |
Normal |
| Familial short stature[34] |
|
Normal | Decreased | Decreased | Normal | Normal | Heterozygous IGF1 Splicing mutation | Normal |
| Constitutional growth delay[35] |
|
Delayed | Normal | Normal | Normal | Normal | Mutations in Variation in FGFR1, GNRHR, TAC3, and TACR3 genes | Normal |
| Growth Hormone Resistance[36] |
|
Delayed | Decreased | Normal |
|
Delayed |
|
Normal |
| Pediatric Hypothyroidism[37] |
|
Delayed | Decreased | Normal |
|
Delayed |
Mutations in:
|
Normal |
| Turner Syndrome[38] |
|
Absent | Decreased | Decreased |
|
Normal | 45 X0 | Normal |
| Silver-Russell Syndrome[39] |
|
Delayed | Decreased | Decreased |
|
Normal | Methylation involving the H19 and IGF2 genes | Normal |
| Noonan Syndrome[40] | Delayed | Decreased | Decreased | Minor facial dysmorphism | Normal | PTPN11 and SOS1 genes abnormality | Normal | |
| Psychosocial Short Stature[41] |
|
Delayed | Decreased | Normal |
|
Normal | Normal | May be low |
| Short stature accompanying systemic disease[42] |
|
Delayed | Decreased | Normal | Failure to thrive | Delayed | Normal | Normal |
| Idiopathic short stature[43] | A height below 2 standard deviations (SD) of the mean for age, in the absence of any endocrine, metabolic, or other diagnosis | Normal | Decreased | Normal | Normal | Delayed | SHOX gene mutations[44] | Normal |
Differentiating hypopituitarism on the basis of ADH deficiency
| Type of DI | Subclass | Disease | Defining signs and symptoms | Lab/Imaging findings |
|---|---|---|---|---|
| Central | Acquired | Histiocytosis |
|
|
| Craniopharyngioma |
|
| ||
| Sarcoidosis |
|
| ||
| Congenital | Hydrocephalus |
|
Dilated ventricles on CT and MRI | |
| Wolfram Syndrome (DIDMOAD) |
| |||
| Nephrogenic | Acquired | Drug-induced (demeclocycline, lithium) |
| |
| Hypercalcemia |
| |||
| Hypokalemia |
| |||
| Multiple myeloma |
|
| ||
| Sickle cell disease |
|
| ||
| Primary polydipsia | Psychogenic |
| ||
| Gestational diabetes insipidus |
| |||
| Diabetes mellitus |
| |||
Hypopituitarism must be differentiated from other causes of headache, polyuria and polydypsia.
| Disease | Causes | Symptoms | Diagnosis and treatment |
|---|---|---|---|
| SIADH | SIADH is a syndrome characterized by excessive release of antidiuretic hormone (ADH or vasopressin) from the posterior pituitary gland or another source. The result is hyponatremia, and sometimes fluid overload |
| |
| Cerebral salt wasting syndrome | Cerebral salt wasting syndrome is defined as therenal loss of sodium during intracranial disease leading to hyponatremia and a decrease in extracellular fluid volume | The patient is | Treatment is |
| Adrenal insufficiency | Adrenal insufficiency
Adrenal insufficiency can be Common causes of primary adrenal insufficiency:
|
Chronic disease is characterized by
Acute addisonian crisis is characterized by: |
The diagnosis of Addisons disease is made through rapid ACTH administration and measurement of cortisol.
The definitive diagnosis is the cosyntropin or ACTH stimulation test. Acortisol level is obtained before and after administering ACTH. A normal person should show a brisk rise in cortisol level after ACTH administration.
Adrenal crisis:
|
| Hypopituitarism | Abnormality in anterior pituitary function
Etiology is as follows: |
Signs and symptoms ofhypopituitarism vary, depending on the deficient hormone and severity of the disorder,some of the symptoms may be as follows:
|
The treatment of permanent hypopituitarism consists of replacement of the peripheral hormones
|
| Hypothyroidism | Hypofunctioning of the thyroid gland due to multifactorial etiology ranging from congenital to autoimmune causes described below:
|
|
Diagnosis of hypothyroidism is based on blood tests:
|
| Psychogenic polydipsia | Also called as primary polydipsia is characterized bypolyuria and polydipsia. Causes are:
|
Evaluation ofpsychiatric patients with polydipsia requires an evaluation for other medical causes of polydipsia, polyuria,hyponatremia, and the syndrome of inappropriate secretion of antidiuretic hormone.
|
References
- ↑ Sato N, Sze G, Endo K (1998). “Hypophysitis: endocrinologic and dynamic MR findings”. AJNR Am J Neuroradiol. 19 (3): 439–44. PMID 9541295.
- ↑ Powrie JK, Powell M, Ayers AB, Lowy C, Sönksen PH (1995). “Lymphocytic adenohypophysitis: magnetic resonance imaging features of two new cases and a review of the literature”. Clin. Endocrinol. (Oxf). 42 (3): 315–22. PMID 7758238.
- ↑ Honegger J, Schlaffer S, Menzel C, Droste M, Werner S, Elbelt U, Strasburger C, Störmann S, Küppers A, Streetz-van der Werf C, Deutschbein T, Stieg M, Rotermund R, Milian M, Petersenn S (2015). “Diagnosis of Primary Hypophysitis in Germany”. J. Clin. Endocrinol. Metab. 100 (10): 3841–9. doi:10.1210/jc.2015-2152. PMID 26262437.
- ↑ Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S (1995). “Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings”. J. Clin. Endocrinol. Metab. 80 (8): 2302–11. doi:10.1210/jcem.80.8.7629223. PMID 7629223.
- ↑ Imura H, Nakao K, Shimatsu A, Ogawa Y, Sando T, Fujisawa I, Yamabe H (1993). “Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus”. N. Engl. J. Med. 329 (10): 683–9. doi:10.1056/NEJM199309023291002. PMID 8345854.
- ↑ Hsieh CY, Liu BY, Yang YN, Yin WH, Young MS (2011). “Massive pericardial effusion with diastolic right ventricular compression secondary to hypothyroidism in a 73-year-old woman”. Emerg Med Australas. 23 (3): 372–5. doi:10.1111/j.1742-6723.2011.01425.x. PMID 21668725.
- ↑ Dejager S, Gerber S, Foubert L, Turpin G (1998). “Sheehan’s syndrome: differential diagnosis in the acute phase”. J. Intern. Med. 244 (3): 261–6. PMID 9747750.
- ↑ Colon-Otero G, Menke D, Hook CC (1992). “A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia”. Med. Clin. North Am. 76 (3): 581–97. PMID 1578958.
- ↑ Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT (2005). “Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society”. J. Clin. Endocrinol. Metab. 90 (1): 581–5, discussion 586–7. doi:10.1210/jc.2004-1231. PMID 15643019.
- ↑ Rugge JB, Bougatsos C, Chou R (2015). “Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force”. Ann. Intern. Med. 162 (1): 35–45. doi:10.7326/M14-1456. PMID 25347444.
- ↑ Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA (2012). “Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association”. Thyroid. 22 (12): 1200–35. doi:10.1089/thy.2012.0205. PMID 22954017.
- ↑ 12.0 12.1 Denschlag, Dominik, MD; Clemens, Tempfer, MD; Kunze, Myriam, MD; Wolff, Gerhard, MD; Keck, Christoph, MD (October 2004), “Assisted reproductive techniques in patients with Klinefelter syndrome: A critical review”, Fertility and Sterility, 82 (4): 775–779, doi:10.1016/j.fertnstert.2003.09.085
- ↑ Virtanen HE, Bjerknes R, Cortes D, Jørgensen N, Rajpert-De Meyts E, Thorsson AV; et al. (2007). “Cryptorchidism: classification, prevalence and long-term consequences”. Acta Paediatr. 96 (5): 611–6. doi:10.1111/j.1651-2227.2007.00241.x. PMID 17462053.
- ↑ Schmitz D, Safranek S (2009). “Clinical inquiries. How useful is a physical exam in diagnosing testicular torsion?”. J Fam Pract. 58 (8): 433–4. PMID 19679025.
- ↑ Trojian TH, Lishnak TS, Heiman D (2009). “Epididymitis and orchitis: an overview”. Am Fam Physician. 79 (7): 583–7. PMID 19378875.
- ↑ Stewart A, Ubee SS, Davies H (2011). “Epididymo-orchitis”. BMJ. 342: d1543. PMID 21490048.
- ↑ Christine Cortet-Rudelli, Didier Dewailly (2006). “Diagnosis of Hyperandrogenism in Female Adolescents”. Hyperandrogenism in Adolescent Girls. Armenian Health Network, Health.am. Unknown parameter
|month=ignored (help) - ↑ Legro RS, Barnhart HX, Schlaff WD (2007). “Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome”. N Engl J Med. 356 (6): 551–566. PMID 17287476.
- ↑ Brunham RC, Gottlieb SL, Paavonen J (2015). “Pelvic inflammatory disease”. N. Engl. J. Med. 372 (21): 2039–48. doi:10.1056/NEJMra1411426. PMID 25992748.
- ↑ Ford GW, Decker CF (2016). “Pelvic inflammatory disease”. Dis Mon. 62 (8): 301–5. doi:10.1016/j.disamonth.2016.03.015. PMID 27107781.
- ↑ Murphy AA (2002). “Clinical aspects of endometriosis”. Ann N Y Acad Sci. 955: 1–10, discussion 34-6, 396–406. PMID 11949938.
- ↑ Rigg LA, Lein A, Yen SS (1977). “Pattern of increase in circulating prolactin levels during human gestation”. Am J Obstet Gynecol. 129 (4): 454–6. PMID 910825.
- ↑ Levy A (2004). “Pituitary disease: presentation, diagnosis, and management”. J Neurol Neurosurg Psychiatry. 75 Suppl 3: iii47–52. doi:10.1136/jnnp.2004.045740. PMC 1765669. PMID 15316045.
- ↑ Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH (1973). “Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone”. J Clin Invest. 52 (9): 2324–9. doi:10.1172/JCI107421. PMC 333037. PMID 4199418.
- ↑ Jha SK, Kannan S (2016). “Serum prolactin in patients with liver disease in comparison with healthy adults: A preliminary cross-sectional study”. Int J Appl Basic Med Res. 6 (1): 8–10. doi:10.4103/2229-516X.173984. PMC 4765284. PMID 26958514.
- ↑ Ben-Menachem, Elinor (2006). “Is Prolactin a Clinically Useful Measure of Epilepsy?”. Epilepsy Currents. 6 (3): 78–79. doi:10.1111/j.1535-7511.2006.00104.x. ISSN 1535-7597.
- ↑ Trimble MR (1978). “Serum prolactin in epilepsy and hysteria”. Br Med J. 2 (6153): 1682. PMC 1608938. PMID 737437.
- ↑ David SR, Taylor CC, Kinon BJ, Breier A (2000). “The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia”. Clin Ther. 22 (9): 1085–96. doi:10.1016/S0149-2918(00)80086-7. PMID 11048906.
- ↑ McCallum RW, Sowers JR, Hershman JM, Sturdevant RA (1976). “Metoclopramide stimulates prolactin secretion in man”. J Clin Endocrinol Metab. 42 (6): 1148–52. doi:10.1210/jcem-42-6-1148. PMID 777023.
- ↑ Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A (1976). “Effects of methyldopa on prolactin and growth hormone”. Br Med J. 1 (6019): 1186–8. PMC 1639736. PMID 1268617.
- ↑ Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA; et al. (2011). “Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline”. J Clin Endocrinol Metab. 96 (2): 273–88. doi:10.1210/jc.2010-1692. PMID 21296991.
- ↑ Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G; et al. (1999). “Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism”. J Clin Endocrinol Metab. 84 (6): 1919–24. doi:10.1210/jcem.84.6.5742. PMID 10372687.
- ↑ Bouali H, Latrech H (2015). “Achondroplasia: Current Options and Future Perspective”. Pediatr Endocrinol Rev. 12 (4): 388–95. PMID 26182483.
- ↑ Kawashima Y, Hakuno F, Okada S, Hotsubo T, Kinoshita T, Fujimoto M; et al. (2014). “Familial short stature is associated with a novel dominant-negative heterozygous insulin-like growth factor 1 receptor (IGF1R) mutation”. Clin Endocrinol (Oxf). 81 (2): 312–4. doi:10.1111/cen.12317. PMID 24033502.
- ↑ Vaaralahti K, Wehkalampi K, Tommiska J, Laitinen EM, Dunkel L, Raivio T (2011). “The role of gene defects underlying isolated hypogonadotropic hypogonadism in patients with constitutional delay of growth and puberty”. Fertil Steril. 95 (8): 2756–8. doi:10.1016/j.fertnstert.2010.12.059. PMID 21292259.
- ↑ Kurtoğlu S, Hatipoglu N (2016). “Growth hormone insensitivity: diagnostic and therapeutic approaches”. J Endocrinol Invest. 39 (1): 19–28. doi:10.1007/s40618-015-0327-2. PMID 26062520.
- ↑ Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G; et al. (2014). “European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism”. Horm Res Paediatr. 81 (2): 80–103. doi:10.1159/000358198. PMID 24662106.
- ↑ Trovó de Marqui AB (2015). “[Turner syndrome and genetic polymorphism: a systematic review]”. Rev Paul Pediatr. 33 (3): 364–71. doi:10.1016/j.rpped.2014.11.014. PMC 4620965. PMID 25765448.
- ↑ Wakeling EL (2011). “Silver-Russell syndrome”. Arch Dis Child. 96 (12): 1156–61. doi:10.1136/adc.2010.190165. PMID 21349887.
- ↑ Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R; et al. (2007). “Germline gain-of-function mutations in RAF1 cause Noonan syndrome”. Nat Genet. 39 (8): 1013–7. doi:10.1038/ng2078. PMID 17603482.
- ↑ Sandberg DE, Gardner M (2015). “Short Stature: Is It a Psychosocial Problem and Does Changing Height Matter?”. Pediatr Clin North Am. 62 (4): 963–82. doi:10.1016/j.pcl.2015.04.009. PMID 26210627.
- ↑ Sanderson IR (2014). “Growth problems in children with IBD”. Nat Rev Gastroenterol Hepatol. 11 (10): 601–10. doi:10.1038/nrgastro.2014.102. PMID 24957008.
- ↑ Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P (2008). “Idiopathic short stature: definition, epidemiology, and diagnostic evaluation”. Growth Horm IGF Res. 18 (2): 89–110. doi:10.1016/j.ghir.2007.11.004. PMID 18182313.
- ↑ Ouni M, Castell AL, Rothenbuhler A, Linglart A, Bougnères P (2015). “Higher methylation of the IGF1 P2 promoter is associated with idiopathic short stature”. Clin Endocrinol (Oxf). doi:10.1111/cen.12867. PMID 26218795.
- ↑ Ghosh KN, Bhattacharya A (1992). “Gonotrophic nature of Phlebotomus argentipes (Diptera: Psychodidae) in the laboratory”. Rev Inst Med Trop Sao Paulo. 34 (2): 181–2. PMID 1340034.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2], Iqra Qamar M.D.[3]
Overview
In a longitudinal survey (1992-1999), the incidence of hypopituitarism was estimated to be 4.2 cases per 100,000. A study comprising two cross-sectional surveys showed the prevalence of hypopituitarism to be 29 – 45.5 per 100.000 individual.
Epidemiology and Demographics
- There is one study performed in northern Spain, regarding hypopituitarism epidemiology combining two cross-sectional surveys (from 1992 and 1999).[1]
Incidence
- In a longitudinal survey (1992-1999), the incidence of hypopituitarism was estimated to be 4.2 cases per 100,000.[1]
- A study was done to find out etiological distribution among 773 adults with hypopituitarism that showed:[2]
- Non-tumoral etiology (50%)
- Pituitary tumors (43.6 %)
- Extra-pituitary tumors (7.2%)
Prevalence
- There is a limited information regarding the prevalence of hypopituitarism.
- The prevalence of hypopituitarism was found to be 29 – 45.5 per 100,000 individual in the two cross-sectional studies.[1]
Gender
- Men and women are affected equally by hypopituitarism.
Age
- Hypopituitarism occurs at any age.
Race
- There is no racial predilection for hypopituitarism.
References
- ↑ 1.0 1.1 1.2 Regal M, Páramo C, Sierra SM, Garcia-Mayor RV (2001). “Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain”. Clin. Endocrinol. (Oxf). 55 (6): 735–40. PMID 11895214.
- ↑ Tanriverdi F, Dokmetas HS, Kebapcı N, Kilicli F, Atmaca H, Yarman S, Ertorer ME, Erturk E, Bayram F, Tugrul A, Culha C, Cakir M, Mert M, Aydin H, Taskale M, Ersoz N, Canturk Z, Anaforoglu I, Ozkaya M, Oruk G, Hekimsoy Z, Kelestimur F, Erbas T (2014). “Etiology of hypopituitarism in tertiary care institutions in Turkish population: analysis of 773 patients from Pituitary Study Group database”. Endocrine. 47 (1): 198–205. doi:10.1007/s12020-013-0127-4. PMID 24366641.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2] Iqra Qamar M.D.[3]
Overview
Common risk factors in the development of hypopituitarism may include pituitary tumor or space occupying lesion, pituitary apoplexy, severe blood loss such as Sheehan’s syndrome, pituitary surgery, cranial radiation, genetic defects, hypothalamic disease, immunosuppression, inflammatory processes, pituitary infarction, and non-compliance with hormone replacement therapy. Less common risk factors, include infiltrative disorders, traumatic brain injury causing skull fractures, ischemic stroke and subarachnoid hemorrhage.
Risk Factors
Common risk factors
Common risk factors of hypopituitarism include the following: [1][2][3][4][3][5][6][7][8]
- Pituitary tumor or space occupying lesion
- Pituitary apoplexy
- Severe loss of blood, such as Sheehan syndrome or postpartum hypopituitarism
- Pituitary surgery, such as hypophysectomy
- Cranial radiation
- Genetic defects
- Hypothalamic disease
- Immunosuppression, such as HIV and high dose glucocorticoid intake
- Inflammatory processes such as hypophysitis
- Pituitary infarction
- Non-compliance with hormone replacement therapy
Less common risk factors
Less common risk factors include:
- Infiltrative disorders such as sarcoidosis and histiocytosis[9]
- Traumatic brain injury causing skull fractures[10][11][12][13][14]
- Ischemic stroke[15]
- Subarachnoid hemorrhage[11][16][17][18]
References
- ↑ Khajeh L, Blijdorp K, Neggers SJ, Ribbers GM, Dippel DW, van Kooten F (2014). “Hypopituitarism after subarachnoid haemorrhage, do we know enough?”. BMC Neurol. 14: 205. doi:10.1186/s12883-014-0205-0. PMC 4207357. PMID 25312299.
- ↑ Vance ML (1994). “Hypopituitarism”. N. Engl. J. Med. 330 (23): 1651–62. doi:10.1056/NEJM199406093302306. PMID 8043090.
- ↑ 3.0 3.1 Jahangiri A, Wagner JR, Han SW, Tran MT, Miller LM, Chen R, Tom MW, Ostling LR, Kunwar S, Blevins L, Aghi MK (2016). “Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis”. J. Neurosurg. 124 (3): 589–95. doi:10.3171/2015.1.JNS141543. PMID 26252454.
- ↑ Snyder PJ, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA (1986). “Hypopituitarism following radiation therapy of pituitary adenomas”. Am. J. Med. 81 (3): 457–62. PMID 3092668.
- ↑ Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML (1989). “Hypopituitarism following external radiotherapy for pituitary tumours in adults”. Q. J. Med. 70 (262): 145–60. PMID 2594955.
- ↑ Eastman RC, Gorden P, Roth J (1979). “Conventional supervoltage irradiation is an effective treatment for acromegaly”. J. Clin. Endocrinol. Metab. 48 (6): 931–40. doi:10.1210/jcem-48-6-931. PMID 447799.
- ↑ Harbeck B, Klose S, Buchfelder M, Brabant G, Lehnert H (2011). “Hypopituitarism in a HIV affected patient”. Exp. Clin. Endocrinol. Diabetes. 119 (10): 633–5. doi:10.1055/s-0031-1284366. PMID 21922454.
- ↑ Morichika D, Sato-Hisamoto A, Hotta K, Takata K, Iwaki N, Uchida K, Minami D, Kubo T, Tanimoto M, Kiura K (2014). “Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: a case report”. Jpn. J. Clin. Oncol. 44 (5): 501–5. doi:10.1093/jjco/hyu019. PMID 24646812.
- ↑ Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, Monson JP, Besser GM, Grossman AB (2000). “Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment”. J. Clin. Endocrinol. Metab. 85 (4): 1370–6. doi:10.1210/jcem.85.4.6501. PMID 10770168.
- ↑ Edwards OM, Clark JD (1986). “Post-traumatic hypopituitarism. Six cases and a review of the literature”. Medicine (Baltimore). 65 (5): 281–90. PMID 3018425.
- ↑ 11.0 11.1 Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E (2007). “Hypopituitarism”. Lancet. 369 (9571): 1461–70. doi:10.1016/S0140-6736(07)60673-4. PMID 17467517.
- ↑ Benvenga S, Campenní A, Ruggeri RM, Trimarchi F (2000). “Clinical review 113: Hypopituitarism secondary to head trauma”. J. Clin. Endocrinol. Metab. 85 (4): 1353–61. doi:10.1210/jcem.85.4.6506. PMID 10770165.
- ↑ Lieberman SA, Oberoi AL, Gilkison CR, Masel BE, Urban RJ (2001). “Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury”. J. Clin. Endocrinol. Metab. 86 (6): 2752–6. doi:10.1210/jcem.86.6.7592. PMID 11397882.
- ↑ Agha A, Thornton E, O’Kelly P, Tormey W, Phillips J, Thompson CJ (2004). “Posterior pituitary dysfunction after traumatic brain injury”. J. Clin. Endocrinol. Metab. 89 (12): 5987–92. doi:10.1210/jc.2004-1058. PMID 15579748.
- ↑ Bondanelli M, Ambrosio MR, Carli A, Bergonzoni A, Bertocchi A, Zatelli MC, Ceruti S, Valle D, Basaglia N, degli Uberti EC (2010). “Predictors of pituitary dysfunction in patients surviving ischemic stroke”. J. Clin. Endocrinol. Metab. 95 (10): 4660–8. doi:10.1210/jc.2010-0611. PMID 20660027.
- ↑ Klose M, Brennum J, Poulsgaard L, Kosteljanetz M, Wagner A, Feldt-Rasmussen U (2010). “Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage”. Clin. Endocrinol. (Oxf). 73 (1): 95–101. doi:10.1111/j.1365-2265.2010.03791.x. PMID 20105184.
- ↑ Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A (2007). “Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review”. JAMA. 298 (12): 1429–38. doi:10.1001/jama.298.12.1429. PMID 17895459.
- ↑ Hannon MJ, Behan LA, O’Brien MM, Tormey W, Javadpour M, Sherlock M, Thompson CJ (2015). “Chronic hypopituitarism is uncommon in survivors of aneurysmal subarachnoid haemorrhage”. Clin. Endocrinol. (Oxf). 82 (1): 115–21. doi:10.1111/cen.12533. PMID 24965315.
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Screening of hypopituitarism has been recommended for the patients with traumatic brain injury and patients with a history of radiation exposure to the head.
Screening
- Hypopituitarism screening has been recommended for patients with traumatic brain injury.[1]
- Screening also is recommended in patients with a history of radiation exposure.
References
- ↑ Ghigo E, Masel B, Aimaretti G, Léon-Carrión J, Casanueva FF, Dominguez-Morales MR; et al. (2005). “Consensus guidelines on screening for hypopituitarism following traumatic brain injury”. Brain Inj. 19 (9): 711–24. doi:10.1080/02699050400025315. PMID 16195185.
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
The natural history of hypopituitarism depends on the severity of damage leading to partial or complete hormonal deficiency. If left untreated, hypopituitarism can lead to critical consequences. Complications of hypopituitarism include adrenal crisis, osteoporosis, electrolyte abnormalities, and diabetes mellitus. Hypopituitarism is often associated with vascular conditions. Hypopituitarism has a good prognosis as long as the hormonal replacement therapy is given adequately.
Natural History
If left untreated, hypopituitarism may lead to the development of different symptoms according to the area/lobe of the pituitary gland affected and the deficient hormone. The natural history is variable and depends upon the severity of damage leading to partial or complete hormonal deficiency, age, rapidity of onset, and the underlying cause:[1]
- In both genders, if left untreated, it will lead to a decrease in bone density and osteoporosis.[2][3][4]
- In women, there may be an increased risk of coronary artery disease due to a reduction estrogen levels.[5][6]
- In men, decreased muscle mass due to a reduction in testosterone hormone levels.
Vasopressin deficiency
- It may lead to dehydration and electrolyte abnormalities such as hypernatremia.
Growth hormone deficiency
- It may lead to serious vascular conditions most likely due to increased serum cholesterol and triglyceride concentrations causing increased mortality.[7][8][9]
Complications
Complications that can develop as a result of hypopituitarism are include:
- Adrenal crisis, the most serious complication of hypopituitarism. It occurs in case of improper glucocorticoids replacement therapy.
- Complications of growth hormone replacement therapy:[10]
Prognosis
- Hypopituitarism has a good prognosis as long as the patient is given optimum hormonal replacement therapy.[1]
- Hypopituitarism is often associated with vascular conditions and has a high mortality rate.[11]
- There are 6 major retrospective studies done that have shown increased mortality in patients with hypopituitarism.[7][12][13][14][15]
References
- ↑ 1.0 1.1 Vance, Mary Lee (1994). “Hypopituitarism”. New England Journal of Medicine. 330 (23): 1651–1662. doi:10.1056/NEJM199406093302306. ISSN 0028-4793.
- ↑ Klibanski, Anne; Neer, Robert M.; Beitins, Inese Z.; Ridgway, E. Chester; Zervas, Nicholas T.; McArthur, Janet W. (1980). “Decreased Bone Density in Hyperprolactinemic Women”. New England Journal of Medicine. 303 (26): 1511–1514. doi:10.1056/NEJM198012253032605. ISSN 0028-4793.
- ↑ Greenspan SL, Oppenheim DS, Klibanski A (1989). “Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism”. Ann. Intern. Med. 110 (7): 526–31. PMID 2923387.
- ↑ Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980). “Decreased bone density in hyperprolactinemic women”. N. Engl. J. Med. 303 (26): 1511–4. doi:10.1056/NEJM198012253032605. PMID 7432421.
- ↑ Matthews, Karen A.; Meilahn, Elaine; Kuller, Lewis H.; Kelsey, Sheryl F.; Caggiula, Arlene W.; Wing, Rena R. (1989). “Menopause and Risk Factors for Coronary Heart Disease”. New England Journal of Medicine. 321 (10): 641–646. doi:10.1056/NEJM198909073211004. ISSN 0028-4793.
- ↑ Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR (1989). “Menopause and risk factors for coronary heart disease”. N. Engl. J. Med. 321 (10): 641–6. doi:10.1056/NEJM198909073211004. PMID 2488072.
- ↑ 7.0 7.1 Rosén T, Bengtsson BA (1990). “Premature mortality due to cardiovascular disease in hypopituitarism”. Lancet. 336 (8710): 285–8. PMID 1973979.
- ↑ Merimee TJ, Hollander W, Fineberg SE (1972). “Studies of hyperlipidemia in the HGH-deficient state”. Metab. Clin. Exp. 21 (11): 1053–61. PMID 4342932.
- ↑ Blackett PR, Weech PK, McConathy WJ, Fesmire JD (1982). “Growth hormone in the regulation of hyperlipidemia”. Metab. Clin. Exp. 31 (2): 117–20. PMID 6804746.
- ↑ Bowlby DA, Rapaport R (2004). “Safety and efficacy of growth hormone therapy in childhood”. Pediatr Endocrinol Rev. 2 Suppl 1: 68–77. PMID 16456485.
- ↑ Prabhakar VK, Shalet SM (2006). “Aetiology, diagnosis, and management of hypopituitarism in adult life”. Postgrad Med J. 82 (966): 259–66. doi:10.1136/pgmj.2005.039768. PMC 2585697. PMID 16597813.
- ↑ Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996). “The effect of hypopituitarism on life expectancy”. J. Clin. Endocrinol. Metab. 81 (3): 1169–72. doi:10.1210/jcem.81.3.8772595. PMID 8772595.
- ↑ Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM (1997). “Increased cerebrovascular mortality in patients with hypopituitarism”. Clin. Endocrinol. (Oxf). 46 (1): 75–81. PMID 9059561.
- ↑ Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B (2000). “Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality”. J. Clin. Endocrinol. Metab. 85 (4): 1420–5. doi:10.1210/jcem.85.4.6498. PMID 10770176.
- ↑ Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM (2001). “Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group”. Lancet. 357 (9254): 425–31. PMID 11273062.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Related Chapters
Related Chapters
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH




